Fine-tuning spatial-temporal dynamics and surface receptor expression support plasma cell-intrinsic longevity

Zhixin Jing[1], Phillip Galbo[2,3], Luis Ovando[1], Megan Demouth[2], Skylar Welte[1], Rosa Park[1], Kartik Chandran[3], Yinghao Wu[3,4], Thomas MacCarthy[5], Deyou Zheng[2,4], David Fooksman[1,2]

Affiliations

[1] Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461

[2] Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461

[3] Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461

[4] Department of System and Computational Biology, Albert Einstein College of Medicine, Bronx, NY 10461

[5] Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY 11794

LEAD CONTACT

David Fooksman, David.fooksman@einsteinmed.edu

HIGHLIGHTS

- LLPCs have reduced motility and increased clustering in the BM
- LLPCs accumulate in the BM PC pool, with mouse age
- LLPCs have unique surfaceome, transcriptome, and BCR clonality
- CXCR4 controls maintenance of PCs and antibody titers

ABSTRACT (199 words)

Durable serological memory following vaccination is critically dependent on the production and survival of long-lived plasma cells (LLPCs). Yet, the factors that control LLPC specification and survival remain poorly resolved. Using intra-vital two-photon imaging, we find that in contrast to most plasma cells in the bone marrow (BM), LLPCs are uniquely sessile and organized into clusters that are dependent on APRIL, an important survival factor. Using deep, bulk RNA sequencing, and surface protein flow-based phenotyping, we find that LLPCs express a unique transcriptome and phenotype compared to bulk PCs, fine tuning expression of key cell surface molecules, CD93, CD81, CXCR4, CD326, CD44 and CD48, important for adhesion and homing. Conditional deletion of *Cxcr4* in PCs following immunization leads to rapid mobilization from the BM, reduced survival of antigen-specific PCs, and ultimately accelerated decay of antibody titer. In naïve mice, the endogenous LLPCs BCR repertoire exhibits reduced diversity, reduced somatic mutations, and increased public clones and IgM isotypes, particularly in young mice, suggesting LLPC specification is non-random. As mice age, the BM PC compartment becomes enriched in LLPCs, which may outcompete and limit entry of new PCs into the LLPC niche and pool.

INTRODUCTION

Prophylactic antibodies induced by vaccines provide rapid, systemic and in some cases, long-lasting immune protection against many infectious diseases. Variability in the duration of antibody responses is chiefly dependent on the composition of short-lived and long-lived plasma cells produced, which can have distinct lifespans of a few days and months or years in mice, respectively [1]. The ability to generate LLPCs also declines with old age, and hence the durability of the vaccine response [2 3]. Therefore, understanding how LLPCs are generated and maintained are essential for enhancing durability of vaccine-induced antibody responses in humans.

Previous studies have reported these LLPCs are enriched in the bone marrow (BM) but can also be found in spleen and mucosa [4-8]. Tracking of endogenous polyclonal LLPCs is challenging, requiring labeling and tracking by thymidine analogs like BrdU, or looking for antigen-specific antibody forming cells by ELISPOTs. However, these approaches are not amenable to tracking live cells by flow cytometry, as there have been no phenotypic markers for endogenous LLPCs, making these cells elusive. Approaches to genetically track LLPCs were recently established [9], which allows studying their turnover and generation.

One major question is how these cells are specified. LLPCs can mature from newly-minted plasmablasts (PBs) in the germinal center that have undergone affinity maturation [10,11]. However, LLPCs can also develop in a T cell-independent manner [12], and B-1 lineages [13], suggesting that there are multiple, distinct pathways to becoming LLPCs, or specification is regulated extrinsically by their niche, or both [14]. Thus, it is unclear if LLPCs arise from unique clones, unique pools of B cells or are just randomly specified from the bulk PC pool, in a stochastic manner, potentially through maturation in the bone marrow niche. Determining what is required for LLPC specification is important for vaccine development.

A second major question regarding LLPCs is how they are maintained and survive in a cell-specific manner. While functionally they are metabolically active, quiescent, murine LLPCs (defined as B220- 2NBDG^{+}) are thought to have minimal transcriptional specificity compared to bulk PCs [15]. In contrast, human LLPCs (CD19^{-} CD138^{high}) have been shown to be transcriptionally distinct from other mature PCs [16] .

The BM is a major lodging site for LLPCs and it is believed that key cell-extrinsic cellular and molecular factors support their longevity. PCs migratory behavior and positioning within BM parenchyma is also linked to chemokine receptor signaling, cell adhesion, cytokine, and age of mice. Previous work from our laboratory found that as PCs age, CXCR4 expression is increased, suggesting LLPCs may upregulate certain key molecules for survival [17]. CXCR4 is a master chemokine receptor for BM tropism but its role in humoral immunity is thought to be dispensable [18]. However, CXCR4 drives PC motility in the BM and is upregulated on PC with aging [17]. We and others have shown that BM PCs are spatially organized in clusters [17,19] and PCs are less motile when they enter these clusters, suggesting extrinsic signals may be important cues for motility. Moreover, in mice lacking APRIL, a key survival cytokine for PCs [20], these clusters were reduced, suggesting clusters and cell dynamics may be functionally important for PC survival.

In this study, we aim to understand what unique features are associated with LLPC physiology, at a molecular, cellular, and spatial-temporal level using cell fate labeling of PCs. We find that these cells exhibit intrinsic changes in gene expression and cell motility patterns that may underlie their unique ability to persist for long periods of time, despite potential competition from a continuously evolving PC pool. Among the factors promoting their survival, CXCR4 plays a dominant cell-intrinsic role in promoting LLPCs retention and survival and thus, maintaining durability of humoral responses.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

Prdm1-EYFP [21] were generated previously and can also be obtained from the Jackson Laboratory. Rosa26-CAG-LSL-tdTomato (Ai14) [22], Rosa26-LSL-EYFP [23], and *Cxcr4*$^{fl/fl}$ [18] were purchased from the Jackson Laboratory. C57BL/6 (CD45.2) and B6-Ly5.1/Cr (CD45.1) mice were purchased from Charles River. All mice were housed in groups of 2–5 animals per cage in SPF facilities at Albert Einstein College of Medicine. The animal protocol in this study was approved by Albert Einstein College of Medicine Institutional Animal Care Use Committee (IACUC). For PC turnover experiments, both females and males that are young (6-8 weeks old) or middle-aged (20-24 weeks old) were used. For mixed bone marrow chimera experiments, 6-8 weeks old sex-matched mice were used as hosts, and 16-24 weeks old WT or CXCR4^{cKO} mice were used as donors.

Blimp1-Cre^{ERT2}-IRES-TdTomato (BEC) mouse were constructed using CRISPR-Cas9 technology on the C57BL/6 background by knocking-in Cre^{ERT2}-IRES-TdTomato cassette downstream of the exon 6 of Prdm1 locus, targeted with one single guide RNA (TCTGTGGGCAGAAACCCGCG). Founders and F1 progenies were genotyped by PCR using primers (Integrated DNA Technologies) targeting *Prdm1* genomic region (5'-GGCAAGATCAAGTATGAGTGC-3', Forward) and IRES sequence (5'-GCCAAAAGACGGCAATATGG-3', Reverse). This mouse line was backcrossed to C57BL/6 for at least three generations. Since BEC is a knock-in knockout allele, only heterozygotes were used for all experiments.

Generation of mixed bone marrow chimera

6-8 weeks old CD45.1 recipient mice were lethally irradiated (950 RAD) and reconstituted with 7-8 x 10^6 50:50 mixture of WT:CXCR4^{cKO} total bone marrow cells, and allowed to recover for 8

weeks with Sulfamethoxazole and Trimethoprim (ANI Pharmaceutials) added to the drinking water (1:50 v/v) in the first 2 weeks post reconstitution.

Immunizations and treatments

For hapten-protein conjugate immunizations, WT or CXCR4^{cKO} mice were immunized intraperitoneally (i.p.) with 50 µg of $NP_{(32)}$-KLH (Biosearch Technologies) in PBS emulsified with alum (Imject Alum; Thermo Fisher Scientific) at 2:1 v:v ratio in 150 µl volume. For PC turnover experiments, 4 mg tamoxifen (MilliporeSigma) were administered by oral gavage per mouse for three consecutive days. For intratibial injection experiments, 5 µg of 4-Hydroxytamoxifen (MilliporeSigma) in 10 µl 5% ethanol (diluted with PBS) was given through shaved knee joint into the tibia using 29G insulin syringes, and 2.5 µg pertussis toxin (MilliporeSigma) in 100 µl volume PBS were intravenously (i.v.) injected to recipient mice. For glucose uptake experiments, 50 µg 2-NBDG (Thermo Fisher Scientific) in 100 µl volume PBS was i.v. injected into mix chimeric mice for exactly 15 min before sacrifice.

Flow cytometry

Single cell suspensions of bone marrow and spleen were resuspended in PBS containing 0.5% BSA and 1 mM EDTA and filtered through a 70 µm nylon mesh. Cells were first stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen). Then they were blocked with anti-CD16/32 (2.4G2, Bio X Cell) and stained for surface proteins with a combination of antibodies on ice for 30min, and analyzed on Cytek Aurora (Cytek Biosciences). Single stains for YFP and TdTomato were prepared using blood cells from Blimp1-YFP mouse and OT-II TdTomato mouse, and all other stains were made by staining wildtype bone marrow cells with individual fluorescently labeled antibody. Compensations were done by automatic live unmix in SpectroFlo software (Cytek Biosciences) during acquisition, followed by manual adjustment of the compensation matrix. To ensure the accuracy of the manual changes in the compensation

matrix, day 5 middle-aged BEC-YFP bone marrow cells were stained with each panel antibody separately to control for the matrix for each marker accordingly such that each stain consists of a basic panel including YFP, TdTomato, CD138-APC, B220-APCCy7, live/dead-CD4/8-BV510, and one of panel markers. Then, for each timepoint (except day 5) analyzed in the PC timestamping experiments, a day 5 middle-aged BEC-YFP mouse stained with all panel antibodies were included as a compensation control. The profiling of the total 19 markers were done by splitting into 3 subpanels with each panel sharing CD138-APC, B220-APCCy7, and live/dead-CD4/8-BV510. The antibody dilution was determined by titrating absolute amount (in μg) per million total bone marrow cells. For intracytoplasmic (4-hydroxy-3-nitrophenyl)acetyl (NP) staining in PCs, surface-stained cells were fixed and permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences), followed by NP-BSA-Fluorescein (Biosearch Tech) staining in 1:200 dilution for 1 hr at 4℃.

Anti-B220 (RA3-6B2), Bcl-2 (BCL/10C4), CD4 (GK1.5), CD8 (53-6.7), CD37 (Duno85), CD44 (IM7), CD45.2 (104), CD48 (HM48-1), CD81 (Eat-2), and CD98 (RL388) were purchased from Biolegend. CD28 (37.51), CD53 (OX-79), CD79b (HM79B), CD93 (AA4.1), CD126 (D7715A7), CD138 (281-2), CD147 (RL73), CD184 (2B11), CD267 (8F10), CD268 (7H22-E16), CD319 (4G2), CD326 (G8.8) were purchased from BD Biosciences. CD3e (145-2C11), CD45.1 (A20) and CD49d (R1-2) were purchased from Fisher Scientific. CD269 (REA550) was purchased from Miltenyi Biotec. Mcl-1 (D2W9E) was purchased from Cell Signaling Technology.

In-vitro assays

For NP-binding ELISA of mouse serum, high-binding 96 well plates (Corning Costar) were coated with 2 μg/ml NP-OVA (Biosearch Tech) in 50 μl volume bicarbonate/carbonate binding buffer (Abcam) overnight at 4℃. Parafilm were used to minimize evaporation of coating buffer inside the plate. Then coating buffer were removed and the plate was blocked with 200 μl PBS

containing 1% BSA per well for 2 hrs at room temperature (RT). After removing blocking buffer, serum samples were added in 50 µl volume with starting dilution at 1:4000 (v:v in blocking buffer) for 4 serial 2-fold dilutions in triplicates, and anti-NP standard antibody (9T13) were added in 50 µl volume with starting concentration at 1 µg/ml for 8 serial 2-fold dilutions in duplicates, followed by incubation for 2 hrs at RT. The plates were washed 4 times with PBS containing 0.05% Tween (PBST) before adding 50 µl peroxidase goat anti-mouse IgG-HRP (Jackson ImmunoReseach) at 1:5000 dilution (v:v in blocking buffer) per well for 1 hr at RT. The plates were again washed 4 times with PBST, followed by adding 50 µl TMB substrate (MilliporeSigma) for 5-10 mins at RT, which is stopped by adding 25 µl sulfuric acid (Thermo Fisher Scientific). The plates were read by EMax Plus microplate reader (Molecular Devices) at 450 nm wavelength using SoftMax Pro 7 software.

Multiphoton intravital imaging and analysis

Surgical preparation for BM intra-tibial imaging was done as previously described [17]. Mice were anesthetized using isoflurane gas during imaging process for 4-5 hours. Z-stack images for multiple regions of tibia were collected sequentially and stitched together either before or after long-term steady state intravital imaging using Olympus software. All imaging was performed using an Olympus FVE-1200 upright microscope, 25x1.04 NA objective, and Deepsee MaiTai Ti-Sapphire pulsed laser (Spectra-Physics) tuned to 920 nm. To maintain mouse body temperature and limit room light exposure, the microscope was fitted with custom-built incubator chamber and heated 37℃ platform. Time lapses were conducted every 3 mins as 100-120 µm deep Z-stacks (5 µm or 3 µm steps) with 1x zoom and with 512 x 512 X-Y resolution. All image analysis was conducted using Imaris software 9.3 (Bitplane) to detect and track LLPCs ($YFP^{+}TdTomato^{bright}$) and bulk PCs ($YFP^{+}TdTomato^{dim}$) in young and middle-aged mice and to correct drift. A ratioed channel (YFP over TdTomato, ch2/ch3) was created together with background subtraction from infrared channel (ch4) to separate LLPCs from bulk PCs. A

threshold of 1.02 in track intensity mean of the ratioed channel was used so that LLPC with higher TdTomato expression would exhibit lower value below the threshold whereas bulk PCs expressing lower TdTomato level would be higher value above the threshold.

Nearest neighbor analysis

LLPCs ($YFP^{+}TdTomato^{bright}$) and bulk PCs ($YFP^{+}TdTomato^{dim}$) in stitched z-stack images were detected as described above. The 2D position coordinates (X and Y) were generated from Imaris built-in spot's function. Nearest neighbor analysis program was created in Fortran using high performance computing. The average distance between individual LLPC spots and 20 nearest total PC spots (combining both LLPCs and bulk PCs), and between individual bulk PC spots and their 20 nearest total PC spots were calculated by the program. Then both LLPC spots and bulk PC spots were randomly picked and the sample size for each subset was determined using 95% confidence level, 5% margin of error, and total number of spots from each mouse inputted as population size. The random picking process was iterated twice per subset. The scripts were executed using a Fortran compiler (cygwin). All code of the data analysis and work flow can be viewed as text document files provided at github link: https://github.com/davidfooksman/nearest-neighbor/

RNA isolation and quantitative real-time RT-PCR

At least 20000 LLPCs ($YFP^{+}TdTomato^{+}$) and 80000 bulk PCs ($YFP^{-}TdTomato^{+}$) from bone marrow or spleen were sorted using Aria III (BD) for total RNA extraction using RNeasy Plus Mini Kit (Qiagen) according to manufacturer's protocol. 30 µl RNase-free water were loaded to the spin column membrane twice to reach higher RNA concentration. 4 µl RNA samples were used for reverse transcription using High-Capacity RNA-to-cDNA Kit (Applied Biosystems) according to manufacturer's protocol. 2 µl cDNA from each sample were used for real time PCR

using TaqMan Universal Master Mix II with UNG (Applied Biosystems) according to manufacturer's protocol. Predesigned TaqMan assays for Actb (Mm02619580_g1) and Cxcr4 (Mm01996749_s1) were purchased from Thermo Fisher Scientific.

Bulk RNA sequencing cDNA library preparation

Bone marrow and splenic PCs were isolated and enriched using $CD138^+$ Plasma Cell Isolation Kit (Miltenyi Biotec), and stained for CD4 (GK1.5) and CD8 (53-6.7) to dump $TdTomato^+$ T cells and DAPI for excluding dead cells before sorting on Aria III (BD) or MoFlo XDP (Beckman Coulter) for RNA extraction. ~1000 $CD4^-CD8^-DAPI^-TdTomato^+$ cells from each enriched samples were sorted into a PCR tube (USA Scientific) containing 0.5 µl 10x reaction buffer and half the final volume of nuclease-free water provided in SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara Bio), and subsequent processes were following manufacturer's protocol. All mixing steps were done by pipetting up and down 5-6 times. ERCC RNA Spike-In Control Mixes (1:5000) (Life Technologies) were added to sorted cells together with lysis buffer. Purification of amplified cDNA was done using Agencourt AMPure XP Kit (Beckman Coulter) on a magnetic separation rack for 1.5 ml tubes (New England Biolabs). The concentration of purified cDNA was determined using Qubit 1X dsDNA HS Assay Kit (Thermo Fisher Scientific) on a Qubit 2.0 fluorometer (Thermo Fisher Scientific). The quality of purified cDNA was verified on a 2100 Bioanalyzer (Agilent Technologies), and the average cDNA fragment size for a typical PC sample was peaked at approximately 600 bp following a normal distribution pattern. Finally, sequencing adaptors were added using Nextera XT DNA Library Preparation Kit (Illumina) following manufacturer's protocol. The library containing all samples was manually mixed to ensure equal final concentration of all samples, and sent for next generation deep sequencing by Genewiz/Azenta using NovaSeq S4 lane machine (Illumina) to reach an average of 50 million reads per sample.

RNA-seq data processing and analysis

RNA-seq reads were aligned to the mouse genome (mm39/GRCm39) using STAR aligner (v2.6.1b) [24]. Counts for individual genes were quantified using the RSEM program (v1.3.1) [25]. Differential expression was computed using the DESeq2 (v 1.26.0), from pair-wise comparisons at adjusted p value < 0.05 (without additional fold change threshold) were collected, clustered by K-mean clustering (k=5), and used for Gene Ontology (GO) enrichment analysis with the patherdb.org server. Enriched GO at adjusted p < 0.05 were obtained and then differentially expressed genes in biologically relevant GO terms for each of the six comparisons were subject to over representation analysis by the Fisher's test, with the results shown as bubble plots. Raw data and processed files were uploaded to the NCBI server (GSE221251).

Transmission electron microscopy

PCs are isolated and enriched the same way as mentioned in the "Bulk RNA sequencing cDNA library preparation" section. 4000-8000 LLPCs ($YFP^{+}TdTomato^{+}$) and 40,000-200,000 bulk PCs ($YFP^{-}TdTomato^{+}$) were subsequently collected by sorting into a 500 µl low adhesion microcentrifuge tubes (USA Scientific) using Aria III (BD) or MoFlo XDP (Beckman Coulter), and 5-6 million sheep red blood cells (Innovative Research) were added to the same tube to provide contrast to the PCs, as previously described (Joyner CJ et al., 2021 Life Science Alliance), which were pelleted by centrifugation at 350g for 5 mins at RT. The supernatant was removed by aspiration, and the fixative containing 2.5% glutaraldehyde in 0.1M cacodylate (prewarmed at RT) was gently added by layering on top of the residual volume of buffer including the cell pellets for 15 mins at RT. Samples were postfixed with 1% osmium tetroxide followed by 2% uranyl acetate, dehydrated through a graded series of ethanol and embedded in LX112 resin (LADD Research Industries, Burlington VT). Ultrathin sections were cut on a Leica Ultracut UC7, stained with uranyl acetate followed by lead citrate and viewed on a JEOL 1400 Plus transmission electron microscope at 120kv.

BCR repertoire analysis

BCR clones were inferred from RNA-Seq data, individually for each sample, using MIXCR v4.0.0b [26] using the following commands:

```
mixcr align -s mmu -p kAligner2
mixcr assemble --write-alignments
mixcr assembleContigs
mixcr exportClones -c IG -p fullImputed
```

The resulting clone files were pre-processed using a custom python script to separate IGH, IGK and IGL clones and to remove small clones of size <10. The resulting datasets were processed using the R package immunarch (https://immunarch.com/). Each repertoire (IGH, IGK, IGL) was loaded using repLoad. Diversity (Chao1) statistics were calculated using repDiversity and repertoire overlaps using repOverlap, For SHM estimates, we used custom R scripts. We filtered out fragmented (lists of sequences with commas), then processed the resulting sequences through IMGT-High V-Quest, which identifies mutations with respect to the closest germline sequence (from IMGT file "8_V-REGION-nt-mutation-statistics.txt"). To avoid double-counting of mutations within a clone, we selected a random sequence from each clone (most clones only had one sequence), then calculated the mean mutation frequency per sequence (number of mutations/V gene length), and then aggregated these to calculate a mean for each IGHV gene allele within each sample (e.g. the mean for all clones assigned to the IGHV8-9*01 allele). Pairwise statistical comparisons between the samples were performed using a paired t-test based on matching alleles (alleles that did not match were not used). Benjamini-Hochberg corrected P values were calculated using the R function p.adjust with the argument method="BH".

Quantification and statistical analyses

Statistical tests were performed using GraphPad Prism (v7 and v8). Specific tests used in each figure are provided in the figure legends with asterisks for statistical significance (*, p-value ≤ 0.05; **, p-value ≤ 0.01; ***, p-value ≤ 0.001; ****, p-value ≤ 0.0001) or "ns" denoting comparisons that are not statistically significant. Data are presented as the mean ± SD or mean

± SEM. For PC half-life ($t_{1/2}$) calculation, the procedure was done exactly as previously described [9]. For RT-qPCR analysis, $2^{-\Delta\Delta Ct}$ method was used to calculate the fold change in *Cxcr4* gene expression relative to the expression of housekeeping gene *Actb* in WT samples.

RESULTS

Plasma cell turnover rate decreases with mouse age

We previously reported that in middle-aged mice, PC motility and clustering within the BM and their recirculation capacity was increased, in comparison to young mice [17]. We speculated that these changes in PC dynamics could alter homeostatic PC turnover rates and may also reflect changes in frequency of LLPCs within PC pool with aging. To study LLPC survival mechanisms, we constructed a novel mouse line, Blimp1-ERT2-Cre-TdTomato (BEC), which contains a tamoxifen-inducible cre recombinase (ERT2-cre) and fluorescent reporter TdTomato under the control of the *Prdm1* (BLIMP1) locus (Figure S1A). We verified that >99% of $CD138^{high}B220^{-}$ BM PCs were $TdTomato^{+}$ (Figure S1B) and that 94% of $TdTomato^{+}$ were ASCs ($CD138^{High}$) (Figure 1A, Figure S1C). Tomato expression was about 1.5-2 log higher than Blimp-1 negative cells, similar to expression by other reporters in the *Prdm1* endogenous locus [27-29]. To label and track lifespans of polyclonal PCs under steady-state conditions, we crossed allele BEC with Rosa26-LSL-EYFP conditional reporter [23] to generate BEC-YFP mouse. Acute treatment with tamoxifen for three consecutive days induced robust Cre-mediated recombination and irreversible expression of YFP, comprised of 98% PCs at day 5 (Figure 1A) but not in the absence of tamoxifen treatment (Figure 1B). Over time, YFP^{+} PCs that survive for months should by definition be bona fide LLPCs. However, in these mice, not all LLPCs would be YFP^{+}, as new LLPCs should develop in the unlabeled (YFP^{-}) fraction.

To study age-related changes in PC turnover, naïve young (6-8 weeks old) and middle-aged (20-24 weeks old) BEC-YFP mice were acutely treated with tamoxifen and tracked over 150 days after treatment (Figure 1C). At day 5 post treatment, both age groups had similar frequency of YFP^{+} PCs in the BM (~65%) and in the spleen (~62%) (Figure 1D). However, over time, the remaining frequency of YFP^{+} cells of total PCs in young mice were significantly lower than in middle-aged mice in both BM and spleen, indicating more PC turnover in the young mice.

At day 150, only 1.8% BM PCs were YFP^+ in young mice compared to 14% in middle-aged mice, while in spleen, 0.6% YFP^+ PCs remained in young mice compared to 3.1% in middle-aged mice (Figure 1E-F). Based on absolute numbers of YFP^+ PCs, we analyzed rate of PC decay in the BM and spleen and found that BM PCs decay more rapidly in young mice ($t_{1/2}$ = 58 days) than in middle-aged mice ($t_{1/2}$ = 93 days) (Figure 1G). In the spleen, decline of labeled PCs was overall faster than in the BM, in line with previous reports [9]. However, we observed that the decline was slightly more rapid in young mice ($t_{1/2}$ = 28 days) as compared to middle-aged mice ($t_{1/2}$ = 39 days) (Figure 1H). Thus, we conclude that homeostatic PC turnover is dependent on tissue-specific microenvironment and aging, suggesting that LLPCs may accumulate with aging, particularly in the bone marrow.

<u>BM LLPCs display cell-intrinsic arrest and clustering</u>

Reduced PC turnover with age, specifically in the BM niche, suggested that PCs were more sessile and better retained in the BM with aging. However, our previous study that showed middle-aged mice had increased overall PC motility and recirculation compared to young mice [17]. We hypothesized that in our previous study, imaging and recirculation measurements did not discriminate between behaviors of LLPCs and immature PCs, which may have different dynamics.

To test this idea, we applied BEC fate labeling to specifically track polyclonal LLPC dynamics and organization in the BM of unimmunized mice. While YFP expression from Rosa26 reporter was bright enough to visualize labeled LLPCs, YFP^- bulk PCs, which also expressed low levels of Tomato from expression of the BEC allele ($Tomato^{dim}$), were insufficiently labeled for deep imaging in the BM. Thus, we bred double PC reporter, Blimp1-YFP BEC *rosa26*$^{LSL\text{-}Tomato}$ mice, in which all PCs were YFP^{high} from expression of the Blimp1-YFP reporter, and with tamoxifen

treatment, could be fate-labeled to co-express high levels of Tomato. We treated these mice with tamoxifen and analyzed surface phenotype of PCs at day 5 and 60 post treatment (Figure 2A). Tomato^{bright} labeled PCs were easily discernable from Tomato^{dim} bulk PCs by flow cytometry (Figure 2B). While at day 5 post treatment, Tomato^{bright} and Tomato^{dim} PCs were similar in PC maturation markers CXCR4 and CD93, by day 60, Tomato^{bright} were phenotypically distinct suggesting they had matured to a LLPC state (explored further in the next section). Using intra-vital time-lapse imaging, we compared Tomato^{bright} and Tomato^{dim} BM PCs dynamics in young and middle-aged mice at day 5, day 30 and day 60 post tamoxifen in order to determine the contribution of intrinsic PC age/maturity to their motility and positioning. We could discriminate and track both PC populations on the basis of Tomato expression in the same time-lapse movies (Figure 2C, Supplemental Video S1). At day 5 after treatment, dynamics of both subsets of PCs were similar, based on cell trajectories, track and displacement velocities, and mean-squared displacement analysis (Figure 2D). However, at day 30 and 60 timepoints, Tomato^{bright} PCs showed reduced motility as compared to Tomato^{dim} PCs indicating PC age correlated with reduced cell motility. This effect with PC aging was seen in both young and middle-aged mice, suggesting it was cell intrinsic, and thus related to LLPC maturation. While average speeds for Tomato^{bright} PCs were relatively slow, some rare PCs were highly motile. At day 30 and 60 timepoints, these fast cells were predominantly in Tomato^{dim} populations (Figure 2E), consistent with immature, short-lived PCs having faster motility than LLPCs.

Next we analyzed LLPC spatial organization, as we and others have shown the bulk BM PCs are organized in clusters [17,19] and that clusters were sites of reduced PC motility [17]. We used two approaches to determine if LLPCs were more clustered than total Bulk PCs. First, we applied our custom script [17] to identify high density PC clusters. We masked these regions and found that at late timepoints after tamoxifen, Tomato^{bright} LLPCs were more enriched in clusters than bulk PCs (Figure 2F-G). As this approach can be sensitive to PC densities, we developed

a second approach to determine if subsets of PCs were enriched in clusters, based on measuring the nearest distance to twenty PC neighbors (Figure 2H). Using this measurement, we found that at day 60, Tomato^{bright} LLPCs were closer to neighboring PCs (i.e., more clustered) than Tomato^{dim} bulk PCs, in the BM of both young and middle-aged mice (Figure 2I). Taken together, while overall PC motility increases with mouse age, most of the increases in motility can be accounted for by bulk PCs and not by LLPCs, which were relatively sessile. This decrease in LLPC motility is also accompanied by an aggregation or retention in PC clusters, suggesting these are LLPC niches, and may be important for their cell-intrinsic survival or retention in the bone marrow.

<u>LLPCs exhibit unique surface phenotype and accumulate in the BM with mouse aging</u>

Based on previous datasets [15,30-32], we curated a candidate list of 19 PC markers, to identify surface markers of LLPCs. We measured normalized surface expression (fold-change) on YFP^{+} LLPCs over YFP^{-} bulk PCs, in the BM and spleen of both young and middle-age BEC-YFP mice at day 5, 30, 90 or 150 post tamoxifen treatment (Figure. 3A). We identified 6 markers that were upregulated (CD93, CD81, CXCR4, and CD326) or 2 downregulated (CD44 and CD48) with PC age (Figure. 3B). For the most part, these changes were subtle, whereas CD93 and CD81 expression showed the largest difference in surface expression with PC age. CD93 expression was uniquely bimodal among all tested markers, with YFP^{+} LLPCs in BM and spleen were predominantly found in CD93^{high} subset, in line with genetic evidence for its importance in LLPC maintenance [33] (Figure. 3C). Expression changes of these factors varied based on mouse age and tissue in some but not all cases (Figure. S2A-C), and also varied by isotype depending on the marker (Figure 3D) suggesting both intrinsic programs and extrinsic signals control LLPC surface phenotype. Several notable markers important for PC survival, were not differentially

expressed, including Syndecan-1 (CD138) (Figure. S2C), BCMA (CD269), and TACI (CD267) involved in in APRIL signaling [34] nor CD28 [35] (Figure 3A).

Previous work used glucose uptake, using the fluorescent analog, 2NBDG, as a marker for LLPCs [15]. Indeed, while LLPCs had a high (~80%) frequency of 2NBDG+ in the BM and spleen (Figure. 3E), there was no difference between bulk PCs and LLPCs in the BM, indicating that metabolism was not linked with maturation in the bone marrow.

Based on changes in PC turnover with age, we hypothesized the overall BM PC pool may become enriched with LLPCs with aging. Using the six differentially expressed surface receptors, we developed an LLPC enrichment panel to identify quasi-LLPCs in WT mice. Using this gating approach, we could enrich for YFP^+ LLPCs in BEC-YFP mice up to 6-fold (Figure. 3F, Fig. S2E). Using this LLPC panel, we found that middle-aged mice had a higher frequency of quasi-LLPCs within the BM PC compartment as compared to young mice (Figure 3G).

Previous transmission electron microscopy (TEM) studies have shown changes in morphology during PC maturation [16,21]. We also sorted YFP^+ LLPCs and YFP^- bulk PCs from the spleen and BM at day 90 and conducted TEM to see if morphological differences accompanied LLPC maturation (Figure S3). Overall, we did not detect statistically significant differences in cell size, cytoplasmic area, mitochondrial density between mature PC subsets, although the distributions had wide ranges. There were minor yet significant changes in nuclear size and chromatin density in splenic LLPCs over BM LLPCs. Taken together, we conclude that differential surface protein expression accompanies cell-intrinsic LLPC maturation, but otherwise cells appear morphologically similar.

<u>CXCR4 controls durability of humoral responses by promoting PC survival and retention in the BM.</u>

CXCR4 is the master chemokine receptor required for lymphocyte entry and retention in the bone marrow [36]. Based on its important role in BM PC motility and retention [17], and its upregulated expression on LLPCs (Figure 3B, 3D), we decided to test if it is required in PCs specifically to maintain humoral responses. Previous work [18] had shown that conditional deletion of *Cxcr4* using a pan B cell expressing cre (CD19-cre) was dispensable for humoral responses and PC survival following vaccination, but potentially this approach did not specifically target PCs and may not be fully penetrant [37].

To delete *Cxcr4* expression in PCs, we bred BEC *rosa26*^{LSLYFP} *Cxcr4*$^{fl/fl}$ mice (or CXCR4^{cKO}). Cohorts of control BEC-YFP (here referred to as WT) and CXCR4^{cKO} mice were immunized (on day -30) with NP-KLH/Alum to generate similar NP-specific PCs and titers at day -3 (Figure 4A-B, Figure S4A-C), at which point, they received tamoxifen to induce *Cxcr4* deletion in CXCR4^{cKO} mice and fate-label PCs with YFP in both groups of mice. We confirmed that *Cxcr4* expression was diminished specifically in YFP^{+} PCs in CXCR4^{cKO} mice at mRNA transcript and protein levels (Figure 4C, Figure S4A) at day 60 in the BM and splenic LLPCs but not in control bulk PCs. Interestingly, CXCR4 surface protein levels were significantly reduced but not completely lost, suggesting incomplete deletion in some cells. Nevertheless, anti-NP titers declined faster in CXCR4^{cKO} mice as compared to WT controls (Figure 4B). Decreases in anti-NP titers were associated with reduced numbers of NP-specific LLPCs (YFP^{+}) in spleen and bone marrow of CXCR4^{cKO} mice as compared to WT mice (Figure 4D).

To determine the role of CXCR4 in homeostatic PC turnover and LLPC competition, we generated chimeric animals using 1:1 ratio of congenically-labeled cells from WT and CXCR4^{cKO} mice. For these studies, mice expressing BEC *rosa26*$^{LSL\text{-}Tomato}$ alleles were used as WT controls. Eight weeks post reconstitution (Figure 4E), mice were treated with tamoxifen and PC decays were tracked over 90 days by flow cytometry. At day 5, fewer PCs were found in the CXCR4^{cKO} vs WT compartment in the bone marrow and spleen (Figure 4F, Figure S4D), suggesting

labeling efficiency was reduced or there was rapid decline in KO PCs cells from the tissue. Correcting for their relative abundance at day 5, labeled WT (Tomato^{bright}) PCs in BM hardly decayed over 90 days, whereas ~50% of CXCR4^{cKO} were lost (Figure 4G, Figure S4E). Within the spleen, PC turnover was overall more rapid, with a 50% and 90% loss of WT and CXCR4^{cKO} labeled PCs, respectively. Overall, WT PCs outcompeted CXCR4^{cKO} PCs in the BM and spleen over time as assessed by competency ratio (Figure 4H, Figure S4F). We analyzed changes in key PC pro-survival factors, Mcl1 and Bcl2 (Figure 4I-J), and found that WT labeled PCs had higher relative expression than CXCR4^{cKO} counterparts, and while they had similar levels at day 5, PC survival was compromised by loss of CXCR4 over time in bone and spleen suggesting CXCR4 is important for long term survival of PCs.

CXCR4 signaling can directly promote cell survival via AKT pathway [38], but it may act indirectly on PC survival by dislodging from survival niches. Thus, we asked if loss of antigen-specific CXCR4^{cKO} PCs was due to cell death in the bone marrow, or egress from the bone marrow niche, eventually leading to PC loss. Chimeric mice were intra-tibially (IT) injected with 4-hydroxy-tamoxifen (4OH-TAM), to induce cre recombination in PC subsets in one bone (Figure 5A). We used this approach previously to track recirculation of BM PCs [17]. At day 1 post injection, WT PCs within the injected tibia were the predominant location of labeled PCs, consistent with a local administration and activity (Figure 5B-C). However, within CXCR4^{cKO} PC pool, most of the labeled PCs were predominantly found in the spleen, but also found at higher frequencies in other bones. This subset-specific effect is unlikely due to leakage of 4OH-TAM to other tissues, as it would have affected both groups of PCs equally. Thus, the likely conclusion is that CXCR4^{cKO} must have rapidly egressed the BM upon cre-deletion of *Cxcr4*. Over time labeled WT PCs egressed the tibia and redistributed to other sites whereas the labeled CXCR4^{cKO} PC remained fixed in spleen and other niches (Figure 5D). To confirm this effect was due to rapid egress, mice were pretreated with pertussis toxin (PTX), which we had found could

block PC motility in the BM [17]. Pretreatment with PTX prevented CXCR4^{cKO} PCs from accumulating in the spleen, following IT-administration of 4-OH-TAM (Figure 5E). Thus, deletion of *Cxcr4* triggers rapid mobilization of PCs from the BM, suggesting dislodging PCs from their niche occurs prior to defects in cell survival.

Shared transcriptional program accompanies BM and splenic LLPC specification

As ASCs mature and migrate to the bone marrow, their transcriptome changes [31]. Based on the changes in surface expression, we hypothesized that LLPCs may also encode a unique transcriptome that fuel these protein expression differences. Based on previous studies of PC transcriptome studies [15], we expected mRNA expression differences in LLPCs to be minor, and due to the over-representation of immunoglobulins in the transcriptome, we performed bulk RNA sequencing with deep reads (50 million reads per sample) to improve our resolution of global changes. For these studies, we FACS-purified matching populations of YFP$^+$ LLPCs and YFP$^-$ bulk PCs from bone marrow and spleen of BEC-YFP mice, on day 90 post tamoxifen treatment. We used groups from both young and middle-aged mice for these studies to see what effect mouse age played in gene expression or PC composition. As negative controls, we also sorted YFP$^+$ and YFP$^-$ PCs from middle-aged mice, on day 5 post treatment. In all, we analyzed 12 groups of PCs (n=3/4 per group, 44 samples total). For these global analyses, we excluded immunoglobulin genes, but analyzed them separately in the next section.

We performed unsupervised clustering of day 90 PC samples using all differentially expressed genes (DEGs) measured by pair-wise comparisons of YFP$^+$ and YFP$^-$ samples, from matching tissues (p_{adj} <0.05, with no cut-offs for fold-change or reads). Based on the sample dendrogram, we found that most LLPC (yellow) and bulk PC (red) samples clustered separately, and within the LLPCs, BM (light green) and splenic (dark green) samples were closely-related (column headings on Figure 6A). Unsupervised clustering of DEGs (rows) revealed five groups of genes (Figure 6A, Supplemental Table 1). Specifically, groups 5 and 2 genes contained DEGs that

were either upregulated or downregulated in all LLPC groups, respectively. Group 1 genes were specifically upregulated in splenic LLPCs, suggesting tissue-specific expression patterns. To better understand the overlaps or similarities of these LLPC groups, we generated an UpSet analysis plot [39,40], based on pair-wise comparisons (Figure 6B). Splenic LLPCs from young and middle-aged mice had the most DEGs, likely because splenic (YFP^-) bulk PCs used in comparisons were highly enriched in short-lived PCs. Among DEGs shared among LLPC subsets, many were shared by 3 or 4 of groups. 12 DEGs were shared by all LLPCs (*Cd55*, *Cxcr3*, *Cyp4f18*, *Fam3c*, *Gpx3*, *H2-Aa*, *H2-Ab1*, *Hcst*, *Prss57*, *Rab3b*, *Slamf6*, *Spag5*). As negative controls, comparisons of day 5 YFP^+ vs YFP^- PCs were conducted, and as expected, very few DEGs were detected or shared with LLPCs. Using circle plots (Figure 6C), we summarized the overlaps of DEGs, and found that BM LLPCs DEGs were more commonly shared among LLPC groups, as compared to splenic LLPCs. We also observed that LLPCs from middle-aged mice had fewer DEGs than young mice, consistent with the view that bulk PCs (YFP^-) are enriched with LLPCs in older mice (Figure 4C).

Next, to determine which biological pathways were altered in LLPCs, we generated GO-terms based on the previously identified DEGs, and assessed term-enrichment in LLPC subsets and day 5 control groups (Figure 6D). As expected, LLPCs showed downregulation of MHC Class II pathway and proliferation related pathways. In contrast, LLPCs showed increased in cell survival and stress response pathways, increased lipid metabolism, and neural-immune signaling. Changes in cell adhesion and chemotaxis were highly enriched in LLPCs and there were also changes in cytokine production pathways. From the total DEG list, putative cell surface receptors were extracted to generate heatmaps of normalized expression among PC subsets in the BM and spleen, clustered by DEG groups (Figure 6E). These included chemokine receptors (*Ccr10*, *Cxcr3*, *Ccr9*, *S1pr1*, *Ebi3*), adhesion molecules (L-selectin, *Ly6* family, Galectins, *Cd93*), MHC-related molecules, co-stimulatory factors (SLAM family, *Tigit*),

and cytokine receptors (*Il6st*, *Il13ra1*, *Ifnar2*, *Tgfb2*) to name a few. Some of these LLPC factors were tissue-specific, such as *C1q* and *Adgre5* expressed by splenic LLPCs. There were notable absences from the list, such as *Cxcr4*, which is upregulated at the protein level in LLPCs, suggesting that minor changes in transcripts may be regulating larger changes at the protein level, or important regulation may be occurring post-transcriptionally [41].

We also generated a putative list of transcription factors (TF) and chromatin-remodeling factors differentially expressed in LLPCs (Figure 6F). Among known PC-related factors, *Bmi1* [42] was upregulated in LLPCs while *Myb* [43], *Klf2* [44] and *Zbtb32* [45] were down-regulated. Interestingly, *Aire* [46] was among the most upregulated LLPC genes, but its role in PCs has not been explored. Many classical PC TFs were not differentially expressed by LLPCs, including *Prdm1* (encoding Blimp1), *Irf4*, and *Xbp1*. Taken together, murine LLPCs exhibit a unique global transcriptome, fine-tuning surface receptors and transcriptional factor expression, which may support longevity.

<u>LLPC receptors have reduced BCR diversity but enriched in public clones.</u>

As expected, the major RNA transcript in these PCs were immunoglobulin heavy and light chains. We assembled over 26,000 complete clones (but not paired sequences) for the BCR heavy and light loci and analyzed their clonal properties, to determine if LLPCs had unique features in different tissues and are from mice of different ages. Notably, these are unselected polyclonal PCs from naïve mice, with unknown antigen specificities.

First, we analyzed isotype usage and found that IgA PCs were the major isotype within the BM and also in the spleen, to a lesser extent (Figure 7A). The one notable exception was that splenic LLPCs from young mice that were time-stamped at 6-8 weeks of age were highly enriched in IgM, in comparison to all other samples, including splenic bulk PCs from same (young) mice. This suggest that these splenic IgM LLPCs are specified early in life and tend to be selectively retained, and maybe derived from B-1 lineages [47]. Within LLPCs subsets, both in

young and middle-aged mice, BM LLPCs have a higher IgA:IgM composition as compared to splenic LLPC counterparts, suggesting tissue-specific homing or retention of different LLPCs on the basis of isotype.

Next, we analyzed diversity of clones in the LLPC and bulk PC subsets, by comparing the heavy chain V-segment + CDR3 exact amino acid sequences. We found that LLPC samples (day 90 YFP^+ BM and spleen) had reduced clonal diversity based on Chao1 estimation index (Figure 7B) as compared to bulk (day 90 YFP^- BM and spleen) PCs, while no differences were observed between YFP^+ and YFP^- subsets at day 5 post TAM. This suggested LLPCs had a reduced repertoire and complexity compared to bulk PCs. This also raised the possibility that different subsets of clones were selected for LLPC fate specification.

To see if LLPC and bulk PCs arise from same pool of B cells, we calculated frequencies of shared clones from different PC groups within the same mouse (Fig. 7C). As expected, PCs from day 5-treated mice showed the highest overlap of clones between YFP^+ and YFP^- subsets in all tissues, along with bulk (YFP^-) PCs in BM and spleen, consistent with their heterogenous PC phenotypes and coordinated timing for PC differentiation. LLPCs in the BM and spleen had more clonal overlap than with matched bulk PCs taken from the same sites. This trend was more striking in young mice, which have fewer LLPCs in the YFP^- subset than in middle-aged mice, suggesting these LLPCs may arise from a different clonal population of B cells in young mice than in middle-aged mice.

LLPCs have been suggested to arise from germinal centers, which could suggest that residency time in the GC may regulate selection into the LLPC pool. To see if polyclonal LLPCs were more highly mutated than total bulk PCs, we compared overall somatic hypermutation (SHM) frequencies in V regions matching samples of YFP^+ (LLPC) and YFP^- (bulk PCs) and found that day 90 LLPC clones had fewer mutations than bulk PCs in BM or spleen whereas no differences in mutations were observed between day 5 samples (Figure 7D). When averaging

all clones per sample, LLPCs also had fewer SHM than paired bulk PC samples in the same tissue of the same mouse. (Figure 7E). LLPCs timestamped at 6-8 weeks (young mice) had even fewer mutations than LLPCs in middle-aged mice. Overall, this confirms that PC cells need not arise from affinity-selected GC B cells in order to enter the LLPC pool.

Finally, to see if certain clones were "public" (or shared by at least 2 samples from different mice), we analyzed heavy chain clonal overlap (as in Figure 7B-C) in all samples. Young mice had the highest overlap of shared public clones compared to other groups (Figure 7F). We analyzed which groups of PCs were responsible for this elevation and found that LLPCs in BM and spleen accounted for most of the public clones (Figure S5A). Next, we analyzed the top 100 most abundant public clones across all samples (Figure S5B) and found a biased enrichment towards LLPC samples (Figure 7G). While LLPCs represented about 28% of all found clones (n= 26144), in the top public clones across samples, 75% were found in LLPC samples from multiple tissues and mice (Figure 7H). Among the top LLPC public clones (found in >75% of LLPC samples, Figure S5B), they were surprisingly absent in bulk PC groups (Figure 7I). This suggests that the some of LLPC endogenous repertoire is directly selected into the LLPC compartment for long term maintenance.

DISCUSSION

The mechanisms and conditions underlying cell fate into long-lived plasma cells following vaccination remains a long-standing question for durable humoral memory. Moreover, once LLPCs are specified, the intrinsic programming and extrinsic factors that control their longevity are still undefined [14,28]. While the field has leaned towards a model that LLPCs arise from late GC B cells [48], LLPCs can be generated by T-independent fashion [6] as well. Recent work using similar PC time-stamping tools have demonstrated that NP-specific LLPCs can arise from pre-

GC stages and accumulate at constant click during the immune response, showing no bias towards late stages [28] nor requiring high affinity for longevity, at least in the NP-immunization model. In “naïve” mice, which are not biased by immunization, we find clones selected into LLPCs pool bear fewer somatic mutations than bulk PCs, consistent with recent scRNA-seq analysis [27], and aforementioned findings that LLPC generation is not strictly dependent on late GC B cells following immunization [28 49]. We also find limited diversity in BCR repertoire, which may reflect unique clones or antigens are pre-programmed for LLPC or, merely that longer immune responses engender more clonal LLPC over time [28]. We also find LLPCs are enriched in public or shared clones, which have been recently shown to be microbial and self-reactive [27,50-52]. Interestingly, while some of our public clone lists have shared V-regions with known self-reactive and microbial specificities, many are not found on any of these lists, suggesting variations in microbiome composition or diet may shift the LLPC clonal composition.

Within the BM, we found that IgA$^+$ LLPCs are the major subset, similar to the bulk BM PC composition, in line with previous studies [9,27], and likely depend on microbial composition in the gut [27,53]. In contrast, the majority of splenic LLPCs are a mix of IgM$^+$ and IgA$^+$ LLPCs, and particularly in young mice, IgM$^+$ LLPCs seem to be specified early and selectively retained in the splenic niche. While IgM$^+$ LLPCs can be generated by various pathways [50,52], and even persist in germ-free mice [51], this early wave of IgM$^+$ LLPCs is consistent with B-1-derived precursors that maintain natural antibodies [47,54]. Indeed, LLPCs timestamped in young mice had more public clones, less diversity and limited SHM. LLPC clones are shared across the BM and splenic compartment, suggesting these niches can be redundant and may accommodate LLPC recirculation between sites [17].

We find unique transcriptome and proteome expressed by endogenous LLPCs that underlie their intrinsic longevity. On the RNA level, these changes are modest [15], and often below detection limits for standard fold-change cut-offs, which may reflect LLPC heterogeneity

[27]. However, these small changes can reflect larger changes in protein levels, as we see for CXCR4, suggesting that proteomics may be a more appropriate way to study changes in PC to LLPC maturation changes. Among the GO-terms and DEGs found, most are shared by LLPCs in the BM or spleen suggesting similar requirements for survival in both sites. One notable exception was cluster 1 of DEGs among splenic LLPCs, which were associated with IgM-specific factors such as complement receptors, consistent with recent studies [7 55].

A major goal here was to address how LLPCs maintain their survival. Mechanistically, is their lifetime intrinsically-regulated [28] or by competition for a limited niche [56]? Our imaging data supports the later model, as LLPCs are preferentially arrested and are more enriched in PCs clusters. Previously, we reported that cluster formation is dependent on hematopoietic-derived APRIL, suggesting it may be enriched in these sites [17]. Thus, both LLPCs and bulk PC (containing short-lived cells) may share and compete for the same cell-extrinsic cues. However, as LLPCs do not express higher levels of APRIL receptors, changes in adhesion receptors may help LLPCs preferentially dock at these niches leading to advantages in survival over newly minted PCs. Additionally, as PCs express different levels of homing and adhesion molecules according to isotype, dynamics and positioning in the BM should vary leading to distinct decay rates.

Among these LLPC intrinsic factors, we found CXCR4 plays a direct functional role in PC survival. Our model directly targets CXCR4 during the PC stage, in an inducible fashion, in contrast with a previous study [18] that used a constitutive deletion of CXCR4 in B cell lineage and found no effect on humoral immunity. While it is tempting to simply conclude that increased CXCR4 expression by LLPCs directly leads to cell-intrinsic arrest in BM niches, we have also showed that CXCR4 promotes BM PC motility, and inhibitors quickly perturb PC motility [17]. In vitro, LLPCs were unresponsive to CXCL12 chemotaxis (data not shown). Moreover, gain-of-

function alleles of CXCR4 also lead to shortened humoral responses but more total PCs [57]. Thus, there may be more complexity to CXCR4 function on PCs in the BM to unravel.

With age, both the number and maturation of PCs increases within the BM [58], which likely affects competition. By intravital imaging, we see that overall polyclonal PC speeds increase in older mice [17], which is likely due to faster motility of short-lived PCs [49] with no sites to dock. Moreover, with aging, decreases in survival factors like APRIL [59], may further limit the survival of newly-minted PC leading to weakened and shortened serological responses, correlating to what is seen in older adults [60,61].

AKNOWLEDGMENTS

We would like to thank Dr. Yongwei Zhang, Einstein Transgenic facility, for helping construct BEC mice, Dr. Xusheng Zhang for help with generating surface marker heat map, Einstein Flow cytometry core for FACS sorting, Einstein Genomics Core for bioanalysis, Einstein Analytical Imaging Facility for help with EM imaging and analysis. This work was supported by R01HL141491 (DRF), Irma T. Hirschl/Monique Weill-Caulier Trusts Research Award (DRF), R01AI132633 (KC) with support from the Albert Einstein NCI Cancer Center grant P30CA013330., SIG #1S10OD016214-01A1. We thank Leslie Cummins for help analyzing and preparing EM images. We thank Dr. Gregoire Lauvau for comments on the manuscript. We would like to dedicate this study to the memory of our friend and co-author, Dr. Thomas MacCarthy.

AUTHOR CONTRIBUTIONS

The study was conceived, designed, by D.R.F. and Z.J, who also wrote the manuscript. Z.J. conducted experiments for all figures. L.O. contributed to Figure 4. R.P. contributed work that supported conclusions in Figure 2. S.W. analyzed EM data in Supplemental Figure 3. K.C. and

M.D. generated unique reagents. P.G., D.Z. analyzed global RNAseq transcriptome Figure 6, and T.M. helped with BCR clonal analysis for Figure 7. Y.H. developed nearest-neighbor analysis for Figure 2.

670

FIGURE LEGENDS

Figure 1. Plasma cell turnover rate decreases with mouse age.

(A), PC purity of TdTomato^{+}YFP^{-} and TdTomato^{+}YFP^{+} cells in BEC-YFP mouse at day 5 post tamoxifen treatment. (B), Percentage of YFP^{+} PCs in BEC-YFP mouse in the absence of tamoxifen treatment or treated for 3 consecutive days and analyzed 5 days after the last treatment. (C), Experimental setup for measuring homeostatic PC turnover rate in young and middle-aged mice by timestamping at day 5, 30, 90, and 150 after oral gavage tamoxifen treatment, accompanied by transcriptional profiling using bulk RNA-seq at day 5 and 90 and morphological characterization using transmission electron microscopy at day 90. (D), FACS pseudo color plots showing decay kinetics of percentage of TdTomato^{+}YFP^{+} in total B220^{-} TdTomato^{+} PCs remaining in the BM (upper panel) and spleen (lower panel) in young and middle-aged mice, quantified in (E) for BM and (F) for spleen. (G) and (H), Absolute numbers (left panel) and half-lives ($t_{1/2}$) (right panel) of TdTomato^{+}YFP^{+} PCs in the BM (H) and spleen (I) in young and middle-aged mice. Curve fitting and $t_{1/2}$ calculations were conducted by using absolute numbers fitted in a one-phase decay model. All bars show mean (E-H) or mean ± SD (G and H). *, P< 0.05; **, P< 0.01; ****, P< 0.0001; ns, non-significant by unpaired Student's t test. All graphs show pooled data from at least two independent experiments. (E, n = 6-18; F, n = 7-13; G, n = 6-21; H, n = 7-13)

Figure 2. BM LLPCs display cell-intrinsic arrest and clustering.

(A), Experimental setup for intratibial two-photon intravital imaging of both TdTomato^{dim}YFP^{+} bulk PCs and TdTomato^{bright}YFP^{+} LLPCs in the same young or middle-aged mouse by timestamping at day 5, 30, and 60 after oral gavage tamoxifen treatment. (B), FACS gating strategy (left panel) for TdTomato^{dim}YFP^{+} bulk PCs and TdTomato^{bright}YFP^{+} LLPCs after intravital imaging and surface CXCR4 and CD93 expression (right panel) on TdTomato^{dim}YFP^{+} bulk PCs

compared to TdTomato^{bright}YFP^{+} LLPCs at day 5 (control timepoint) and day 60 post tamoxifen treatment. (C), Time-lapse images highlighting the cell migration trajectories of 4 bulk PCs (green spot with light purple tracks) and 2 LLPCs (yellow spots with red tracks) in a small region of BM parenchyma. Scale bars, 7 μm. (D), Individual cell tracks of total bulk PCs or LLPCs plotted at a common origin (left panel) in young and middle-aged mice at day 5, 30, and 60 post tamoxifen treatment. Comparison of total bulk PCs and LLPCs track velocity (middle left panel), track displacement velocity (middle right panel), and mean-squared displacement (right panel) in young and middle-aged mice at day 5, 30, and 60 post tamoxifen treatment. (E), Fractions of fast-moving cells (track velocity > 1 μm/min) in bulk PCs compared to LLPCs at day 30 and 60 post tamoxifen treatment. Data were pooled from young and middle-aged mice for each timepoint. (F) Representative intravital 3D flattened image of masked intensity channels of bulk PCs (green) and LLPCs (yellow) (upper panel) and PC spots (bulk PCs in green and LLPCs in yellow) and cluster surfaces (purple) (lower panel) identified for analysis in (G). (G), Average percentage of bulk PCs compared to LLPCs staying inside cluster surface over time (left panel). Average time of individual bulk PCs spent inside cluster surface compared to that of LLPCs (right panel). (H) Depiction of nearest neighbor analysis for cell-cell distance (lines) in 3D (collapsed in 2D) between bulk PCs (green) and total PCs (green and orange), or between LLPCs (orange) and total PCs (green and orange), which is quantified in (I) for an average distance between bulk PCs or LLPCs and their 20 nearest neighbor cells (total PCs combining bulk PCs and LLPCs). Each symbol represents one randomly picked cell per subset, and data were pooled from at least two mice. All bars show mean (D and I). *, P< 0.05; **, P< 0.01; ****, P< 0.0001; exact p-values; ns, non-significant by Mann Whitney U test (D), Kruskal-Wallis test with Dunn's test for multiple comparisons (I), or paired Student's t test (E and G). All graphs show pooled data from at least two independent experiments. (E, n = 3-5; G, n = 4)

<u>Figure 3. Differentially expressed surface receptors accompany LLPC maturation.</u>

(A), Heatmap depicting average fold changes of surface marker expression level (gMFI) on TdTomato$^+$YFP$^+$ LLPCs and TdTomato$^+$YFP$^-$ bulk PCs from 3-4 mice per unit at indicated timepoints post tamoxifen treatment in the bone marrow and spleen of young and middle-aged mice. Color scale showing fold increase in red, fold decrease in blue, or no difference in white. (B), Overlay histograms comparing the expression level of differentially expressed surface markers on TdTomato$^+$YFP$^-$ bulk PCs to TdTomato$^+$YFP$^+$ LLPCs at day 90 post tamoxifen treatment. (C). Percentage of CD93$^+$ cells on TdTomato$^+$YFP$^+$ LLPCs relative to TdTomato$^+$YFP$^-$ bulk PCs in individual mouse at indicated timepoints post tamoxifen treatment in the bone marrow (left panel) and spleen (right panel) of young and middle-aged mice. (D) The fold change of the expression level (gMFI) of differentially expressed surface markers of isotype-specific or total TdTomato$^+$YFP$^+$ LLPCs relative to matching isotype TdTomato$^+$YFP$^-$ bulk PCs in individual mouse at day 90 post tamoxifen treatment in young BEC-YFP mice. (E) Analysis of 2NBDG$^+$ population within LLPC and bulk PC subsets at indicated timepoints. (F). Percentage of TdTomato$^+$YFP$^+$ LLPCs pre and post enrichment using a combination of 6 antibody panel of differentially expressed surface markers identified in Fig. 3B. No enrichment represents the percentage of TdTomato$^+$YFP$^+$ LLPCs at day 90 post tamoxifen in young mice. (G), Percentage of quasi-LLPCs in total PCs identified using 6-marker antibody panel in young and middle-aged mice at steady state. All bars show mean ± SEM (C-E). *, P< 0.05; **, P< 0.01; ***, P< 0.001; ****, P< 0.0001; ns, non-significant by unpaired Student's t test. All graphs show pooled data from at least two independent experiments. (A,C-E, n = 3-7; G, n = 5-6 mice)

<u>Fig. 4. CXCR4 controls durable humoral response by promoting PC survival</u>

(A), Experimental set up for examining the role of CXCR4 in sustaining antigen-specific antibody responses using a NP-KLH/Alum immunization model. i.p., intraperitoneal. (B), Anti-NP antibody titer in WT or CXCR4^{cKO} mice before tamoxifen treatment at day 30 post immunization (left panel) and the remaining percentage of pre-treat anti-NP antibody at indicated timepoints post

tamoxifen treatment (right panel). (C), Fold change of FACS-purified YFP^+ PCs *Cxcr4* mRNA level in WT or $CXCR4^{cKO}$ mice, normalized to *Actb* levels in WT mice. (D), Absolute numbers of NP-specific bulk PCs and LLPCs in the bone marrow (left panel) and spleen (right panel) of WT and $CXCR4^{cKO}$ mice. (E), Experimental set up for generating mixed bone marrow chimera reconstituted with WT and $CXCR4^{cKO}$ donors. (F), Absolute number of (YFP^+) labeled BM and spleen PCs at indicated timepoints post tamoxifen treatment (G) normalized labeled PC numbers shown in (F) (relative to day 5 post tamoxifen treatment). (H) PC competitive competency (right panel) at indicated timepoints determined by normalizing the $CXCR4^{cKO}$:WT ratio in the bone marrow labeled PC compartment to that of total splenic B cell compartment (upper panels) or the $CXCR4^{cKO}$:WT ratio in the splenic labeled PC compartment to that of total splenic B cell compartment (lower panels). (I and J), Mcl1 (I) and Bcl2 (J) intracytoplasmic expression (by gMFI) of WT or $CXCR4^{cKO}$ labeled PC compartment at indicated timepoints in the bone marrow (left panel) and spleen (right panel). Fold changes of WT over $CXCR4^{cKO}$ labeled PCs in Mcl1 and Bcl2 expression level are indicated above the statistical significance symbol. All bars show mean ± SEM. Each symbol in all plots represents one mouse. *, $P< 0.05$; **, $P< 0.01$; ***, $P< 0.001$; ****, $P< 0.0001$; ns, non-significant by unpaired Student's t test (B, C, D, F-G, L, and M), paired Student's t test (I and J) or one-way ANOVA with multiple comparison correction using the Holm-Šídák test (H). All graphs show pooled data from two independent experiments. (B, n = 13-15 (left), n = 6-9 (right); C, n = 4-8; D, n = 6-9; F-H, n = 8-10; I, n = 8-10; J, n = 8-10)

<u>Figure 5. CXCR4 retains PCs in the BM</u>

(A), Experimental set up for intratibial injection into WT:$CXCR4^{cKO}$ mixed bone marrow chimera in the presence or absence of pertussis toxin treatment. (B), Absolute number of labeled WT or $CXCR4^{cKO}$ PC in injected tibia and distal organs/tissues at day 1 post 4-OH-TAM injection. (C), Distribution of absolute numbers of labeled WT or $CXCR4^{cKO}$ PCs in injected tibia and distal

organs/tissues. (D), FACS pseudo color plot showing the percentage of labeled PCs in injected tibia and other distal organs/tissues at day 1 post intratibial injection. (E) Absolute number of labeled CXCR4^{cKO} (left panel) or WT (right panel) PCs in injected tibia and distal organs/tissues at day 1 post 4-OH-TAM injection in the presence or absence of pertussis toxin (PTX). All bars show mean ± SEM. Each symbol in all plots represents one mouse. *, P< 0.05; **, P< 0.01; ***, P< 0.001; ****, P< 0.0001; ns, non-significant by unpaired Student's t test (E), paired Student's t test (B) or one-way ANOVA with multiple comparison correction using the Holm-Šídák test (E). All graphs show pooled data from two independent experiments. (B, n = 4; E, n = 3)

Figure 6. Shared transcriptional program accompanies BM and splenic LLPC specification

(A), Heatmap depicting unsupervised clustering of total differentially expressed genes (DEGs, p_{adj}-value < 0.05) between TdTomato^{+}YFP^{-} bulk PCs to TdTomato^{+}YFP^{+} LLPCs across tissue types (bone marrow and spleen) and mouse ages (young and middle-aged) at day 90 post tamoxifen treatment, with no cutoff for fold change and transcripts per million reads (TPM). Color scale represents z-score for normalization per gene (row). Total DEGs were separated in 5 color-coded clusters. (B), UpSet plot visualizing total number of DEGs in each pair-wise comparison (single node) and intersections (connecting nodes) between DEGs among different pair-wise comparisons. (C), Pie charts showing the fractions of the DEGs that are unique in one pair-wise comparison group or shared by 2-4 groups of pair-wise comparisons. Numbers in the center of each chart represents the total number of DEGs in each indicated pair-wise comparison group. (D), Bubble plots showing selected gene ontology terms (GO terms) enrichment comparing LLPCs groups (highlighted in yellow) and day 5 control groups bulk PCs (highlighted in red) based on previously identified DEGs in (A). Color scale bar showing the percentage of DEGs upregulated per GO term in each pair-wise comparison group (red, > 50% upregulated DEGs; blue, < 50% upregulated DEGs). Circle size represents the significance of

the enrichment based on the -log10(p-value). (E and F), Heatmap of all DEGs encoding surface proteins (E) or transcription factors (F) between LLPC groups and bulk PC groups in both the spleen (left) and the bone marrow (right), which are further separated by gene clusters identified in (A).

Figure 7. LLPC receptors have reduced BCR diversity but enriched in public clones.

(A), Stacked bar plots showing isotype gene usage (the fraction of isotypes in total mapped complete clones per group) in LLPCs and bulk PCs at day 5 and 90 post tamoxifen treatment across tissue types (spleen and bone marrow) and mouse ages (young and middle-aged). Line thickness represents the statistical significance based on p-value thresholds. Line color represents the comparisons of color-coded isotypes between groups. (B), BCR repertoire diversity of LLPCs and bulk PCs at indicated timepoints across tissue types (spleen and bone marrow) and mouse ages (young and middle-aged), estimated by chao 1 richness index for the abundance of unique clones in a repertoire per group. Each symbol represents one mouse, and pooled bulk PC samples comparing pooled LLPC samples at day 90 post tamoxifen treatment were shown on the right in black. (C), The percentage of clones shared by indicated PC subsets within the same mouse (intra-mouse). X axis format (A::B) reflects samples A & B used for comparison. (D), Violin plots comparing the distribution of somatic mutation frequencies per specific V region (across all clones) in YFP^- bulk PCs and YFP^+ LLPCs at indicated timepoints in young and middle-aged mice. Each symbol represents one clone, and multiple samples were pooled from each group. (E), Average mutation frequencies of all clones in (D) for each PC subset in indicated tissues in young and middle-aged mice. Each symbol represents one mouse. (F), The percentage of clones shared by all samples, day 5 samples, middle-aged mice samples, and young samples. Each symbol represents one sample (e.g., BM YFP^+ sample, BM YFP^- sample, etc.). (G), Frequency of top 100 most abundant public clones in all PC samples compared to that in LLPC samples. Clones showing no preference for LLPC samples over total

samples are distributed on the diagonal line in the plot. Each symbol represents a clone. (H), Pie charts showing the fraction of total clones or top 100 most abundant public clones in LLPCs compared to other PCs. (I), Stacked bar plots showing the distribution of sample types (in tissues and age of mice) per most frequent public clone in LLPCs. Number on the right of each stacked bar represents the number of mice. *, P< 0.05; **, P< 0.01; ****, P< 0.0001; exact p-values for non-significance by unpaired Student's t test.

References

1. Sze, D.M., Toellner, K.M., Garcia de Vinuesa, C., Taylor, D.R., and MacLennan, I.C. (2000). Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. The Journal of experimental medicine *192*, 813-821.
2. Frasca, D., and Blomberg, B.B. (2020). Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing *17*, 37. 10.1186/s12979-020-00210-z.
3. Palacios-Pedrero, M.A., Osterhaus, A., Becker, T., Elbahesh, H., Rimmelzwaan, G.F., and Saletti, G. (2021). Aging and Options to Halt Declining Immunity to Virus Infections. Frontiers in immunology *12*, 681449. 10.3389/fimmu.2021.681449.
4. Manz, R.A., Thiel, A., and Radbruch, A. (1997). Lifetime of plasma cells in the bone marrow. Nature *388*, 133-134. 10.1038/40540.
5. Slifka, M.K., Antia, R., Whitmire, J.K., and Ahmed, R. (1998). Humoral immunity due to long-lived plasma cells. Immunity *8*, 363-372.
6. Bortnick, A., Chernova, I., Quinn, W.J., 3rd, Mugnier, M., Cancro, M.P., and Allman, D. (2012). Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. J Immunol *188*, 5389-5396. 10.4049/jimmunol.1102808.
7. Bohannon, C., Powers, R., Satyabhama, L., Cui, A., Tipton, C., Michaeli, M., Skountzou, I., Mittler, R.S., Kleinstein, S.H., Mehr, R., et al. (2016). Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection. Nat Commun *7*, 11826. 10.1038/ncomms11826.
8. Lemke, A., Kraft, M., Roth, K., Riedel, R., Lammerding, D., and Hauser, A.E. (2016). Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice. Mucosal Immunol *9*, 83-97. 10.1038/mi.2015.38.
9. Xu, A.Q., Barbosa, R.R., and Calado, D.P. (2020). Genetic timestamping of plasma cells in vivo reveals tissue-specific homeostatic population turnover. eLife *9*. 10.7554/eLife.59850.
10. Takahashi, Y., Dutta, P.R., Cerasoli, D.M., and Kelsoe, G. (1998). In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. The Journal of experimental medicine *187*, 885-895.
11. Phan, T.G., Paus, D., Chan, T.D., Turner, M.L., Nutt, S.L., Basten, A., and Brink, R. (2006). High affinity germinal center B cells are actively selected into the plasma cell compartment. The Journal of experimental medicine *203*, 2419-2424. 10.1084/jem.20061254.
12. Bortnick, A., and Allman, D. (2013). What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens. J Immunol *190*, 5913-5918. 10.4049/jimmunol.1300161.
13. Vergani, S., Muleta, K.G., Da Silva, C., Doyle, A., Kristiansen, T.A., Sodini, S., Krausse, N., Montano, G., Kotarsky, K., Nakawesi, J., et al. (2022). A self-sustaining layer of early-life-origin B cells drives steady-state IgA responses in the adult gut. Immunity *55*, 1829-1842 e1826. 10.1016/j.immuni.2022.08.018.
14. Robinson, M.J., Webster, R.H., and Tarlinton, D.M. (2020). How intrinsic and extrinsic regulators of plasma cell survival might intersect for durable humoral immunity. Immunological reviews *296*, 87-103. 10.1111/imr.12895.

872 15. Lam, W.Y., Jash, A., Yao, C.H., D'Souza, L., Wong, R., Nunley, R.M., Meares, G.P., Patti, G.J., and
873 Bhattacharya, D. (2018). Metabolic and Transcriptional Modules Independently Diversify Plasma
874 Cell Lifespan and Function. Cell reports *24*, 2479-2492 e2476. 10.1016/j.celrep.2018.07.084.
875 16. Joyner, C.J., Ley, A.M., Nguyen, D.C., Ali, M., Corrado, A., Tipton, C., Scharer, C.D., Mi, T.,
876 Woodruff, M.C., Hom, J., et al. (2022). Generation of human long-lived plasma cells by
877 developmentally regulated epigenetic imprinting. Life Sci Alliance *5*. 10.26508/lsa.202101285.
878 17. Benet, Z., Jing, Z., and Fooksman, D.R. (2021). Plasma cell dynamics in the bone marrow niche.
879 Cell reports *34*, 108733. 10.1016/j.celrep.2021.108733.
880 18. Nie, Y., Waite, J., Brewer, F., Sunshine, M.J., Littman, D.R., and Zou, Y.R. (2004). The role of
881 CXCR4 in maintaining peripheral B cell compartments and humoral immunity. The Journal of
882 experimental medicine *200*, 1145-1156. 10.1084/jem.20041185.
883 19. Mokhtari, Z., Mech, F., Zehentmeier, S., Hauser, A.E., and Figge, M.T. (2015). Quantitative image
884 analysis of cell colocalization in murine bone marrow. Cytometry A *87*, 503-512.
885 10.1002/cyto.a.22641.
886 20. Benson, M.J., Dillon, S.R., Castigli, E., Geha, R.S., Xu, S., Lam, K.P., and Noelle, R.J. (2008). Cutting
887 edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J
888 Immunol *180*, 3655-3659. 10.4049/jimmunol.180.6.3655.
889 21. Fooksman, D.R., Schwickert, T.A., Victora, G.D., Dustin, M.L., Nussenzweig, M.C., and Skokos, D.
890 (2010). Development and migration of plasma cells in the mouse lymph node. Immunity *33*, 118-
891 127. 10.1016/j.immuni.2010.06.015.
892 22. Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Palmiter,
893 R.D., Hawrylycz, M.J., Jones, A.R., et al. (2010). A robust and high-throughput Cre reporting and
894 characterization system for the whole mouse brain. Nat Neurosci *13*, 133-140. 10.1038/nn.2467.
895 23. Srinivas, S., Watanabe, T., Lin, C.S., William, C.M., Tanabe, Y., Jessell, T.M., and Costantini, F.
896 (2001). Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26
897 locus. BMC Dev Biol *1*, 4. 10.1186/1471-213x-1-4.
898 24. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
899 Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics *29*, 15-21.
900 10.1093/bioinformatics/bts635.
901 25. Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with
902 or without a reference genome. BMC Bioinformatics *12*, 323. 10.1186/1471-2105-12-323.
903 26. Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V., and
904 Chudakov, D.M. (2015). MiXCR: software for comprehensive adaptive immunity profiling. Nature
905 methods *12*, 380-381. 10.1038/nmeth.3364.
906 27. Liu, X., Yao, J., Zhao, Y., Wang, J., and Qi, H. (2022). Heterogeneous plasma cells and long-lived
907 subsets in response to immunization, autoantigen and microbiota. Nature immunology *23*,
908 1564-1576. 10.1038/s41590-022-01345-5.
909 28. Robinson, M.J., Dowling, M.R., Pitt, C., O'Donnell, K., Webster, R.H., Hill, D.L., Ding, Z., Dvorscek,
910 A.R., Brodie, E.J., Hodgkin, P.D., et al. (2022). Long-lived plasma cells accumulate in the bone
911 marrow at a constant rate from early in an immune response. Sci Immunol *7*, eabm8389.
912 10.1126/sciimmunol.abm8389.
913 29. Kallies, A., Hasbold, J., Tarlinton, D.M., Dietrich, W., Corcoran, L.M., Hodgkin, P.D., and Nutt, S.L.
914 (2004). Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. The Journal
915 of experimental medicine *200*, 967-977.
916 30. Akhmetzyanova, I., Aaron, T., Galbo, P., Tikhonova, A., Dolgalev, I., Tanaka, M., Aifantis, I., Zheng,
917 D., Zang, X., and Fooksman, D. (2021). Tissue-resident macrophages promote early
918 dissemination of multiple myeloma via IL-6 and TNFalpha. Blood Adv *5*, 3592-3608.
919 10.1182/bloodadvances.2021005327.

920 31. Shi, W., Liao, Y., Willis, S.N., Taubenheim, N., Inouye, M., Tarlinton, D.M., Smyth, G.K., Hodgkin,
921 P.D., Nutt, S.L., and Corcoran, L.M. (2015). Transcriptional profiling of mouse B cell terminal
922 differentiation defines a signature for antibody-secreting plasma cells. Nature immunology *16*,
923 663-673. 10.1038/ni.3154.
924 32. Cornelis, R., Hahne, S., Taddeo, A., Petkau, G., Malko, D., Durek, P., Thiem, M., Heiberger, L.,
925 Peter, L., Mohr, E., et al. (2020). Stromal Cell-Contact Dependent PI3K and APRIL Induced NF-
926 kappaB Signaling Prevent Mitochondrial- and ER Stress Induced Death of Memory Plasma Cells.
927 Cell Rep *32*, 107982. 10.1016/j.celrep.2020.107982.
928 33. Chevrier, S., Genton, C., Kallies, A., Karnowski, A., Otten, L.A., Malissen, B., Malissen, M., Botto,
929 M., Corcoran, L.M., Nutt, S.L., and Acha-Orbea, H. (2009). CD93 is required for maintenance of
930 antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci
931 U S A *106*, 3895-3900. 10.1073/pnas.0809736106.
932 34. McCarron, M.J., Park, P.W., and Fooksman, D.R. (2017). CD138 mediates selection of mature
933 plasma cells by regulating their survival. Blood *129*, 2749-2759. 10.1182/blood-2017-01-761643.
934 35. Utley, A., Chavel, C., Lightman, S., Holling, G.A., Cooper, J., Peng, P., Liu, W., Barwick, B.G., Gavile,
935 C.M., Maguire, O., et al. (2020). CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell
936 Survival. Cell reports *31*, 107815. 10.1016/j.celrep.2020.107815.
937 36. Zehentmeier, S., and Pereira, J.P. (2019). Cell circuits and niches controlling B cell development.
938 Immunological reviews *289*, 142-157. 10.1111/imr.12749.
939 37. Aaron, T.S., and Fooksman, D.R. (2022). Dynamic organization of the bone marrow plasma cell
940 niche. FEBS J *289*, 4228-4239. 10.1111/febs.16385.
941 38. Scotton, C.J., Wilson, J.L., Scott, K., Stamp, G., Wilbanks, G.D., Fricker, S., Bridger, G., and Balkwill,
942 F.R. (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human
943 ovarian cancer. Cancer research *62*, 5930-5938.
944 39. Conway, J.R., Lex, A., and Gehlenborg, N. (2017). UpSetR: an R package for the visualization of
945 intersecting sets and their properties. Bioinformatics *33*, 2938-2940.
946 10.1093/bioinformatics/btx364.
947 40. Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R., and Pfister, H. (2014). UpSet: Visualization of
948 Intersecting Sets. IEEE Trans Vis Comput Graph *20*, 1983-1992. 10.1109/TVCG.2014.2346248.
949 41. Greenbaum, D., Colangelo, C., Williams, K., and Gerstein, M. (2003). Comparing protein
950 abundance and mRNA expression levels on a genomic scale. Genome Biol *4*, 117. 10.1186/gb-
951 2003-4-9-117.
952 42. Di Pietro, A., Polmear, J., Cooper, L., Damelang, T., Hussain, T., Hailes, L., O'Donnell, K., Udupa,
953 V., Mi, T., Preston, S., et al. (2022). Targeting BMI-1 in B cells restores effective humoral immune
954 responses and controls chronic viral infection. Nature immunology *23*, 86-98. 10.1038/s41590-
955 021-01077-y.
956 43. Good-Jacobson, K.L., O'Donnell, K., Belz, G.T., Nutt, S.L., and Tarlinton, D.M. (2015). c-Myb is
957 required for plasma cell migration to bone marrow after immunization or infection. The Journal
958 of experimental medicine *212*, 1001-1009. 10.1084/jem.20150191.
959 44. Winkelmann, R., Sandrock, L., Porstner, M., Roth, E., Mathews, M., Hobeika, E., Reth, M., Kahn,
960 M.L., Schuh, W., and Jack, H.M. (2011). B cell homeostasis and plasma cell homing controlled by
961 Kruppel-like factor 2. Proc Natl Acad Sci U S A *108*, 710-715. 10.1073/pnas.1012858108.
962 45. Jash, A., Zhou, Y.W., Gerardo, D.K., Ripperger, T.J., Parikh, B.A., Piersma, S., Jamwal, D.R., Kiela,
963 P.R., Boon, A.C.M., Yokoyama, W.M., et al. (2019). ZBTB32 restrains antibody responses to
964 murine cytomegalovirus infections, but not other repetitive challenges. Sci Rep *9*, 15257.
965 10.1038/s41598-019-51860-z.
966 46. Mathis, D., and Benoist, C. (2009). Aire. Annu Rev Immunol *27*, 287-312.
967 10.1146/annurev.immunol.25.022106.141532.

968 47. Baumgarth, N. (2016). B-1 Cell Heterogeneity and the Regulation of Natural and Antigen-
969 Induced IgM Production. Frontiers in immunology *7*, 324. 10.3389/fimmu.2016.00324.
970 48. Weisel, F.J., Zuccarino-Catania, G.V., Chikina, M., and Shlomchik, M.J. (2016). A Temporal Switch
971 in the Germinal Center Determines Differential Output of Memory B and Plasma Cells. Immunity
972 *44*, 116-130. 10.1016/j.immuni.2015.12.004.
973 49. Koike, T., Fujii, K., Kometani, K., Butler, N.S., Funakoshi, K., Yari, S., Kikuta, J., Ishii, M., Kurosaki,
974 T., and Ise, W. (2023). Progressive differentiation toward the long-lived plasma cell
975 compartment in the bone marrow. The Journal of experimental medicine *220*.
976 10.1084/jem.20221717.
977 50. Blanc, P., Moro-Sibilot, L., Barthly, L., Jagot, F., This, S., de Bernard, S., Buffat, L., Dussurgey, S.,
978 Colisson, R., Hobeika, E., et al. (2016). Mature IgM-expressing plasma cells sense antigen and
979 develop competence for cytokine production upon antigenic challenge. Nat Commun *7*, 13600.
980 10.1038/ncomms13600.
981 51. Lino, A.C., Dang, V.D., Lampropoulou, V., Welle, A., Joedicke, J., Pohar, J., Simon, Q., Thalmensi,
982 J., Baures, A., Fluhler, V., et al. (2018). LAG-3 Inhibitory Receptor Expression Identifies
983 Immunosuppressive Natural Regulatory Plasma Cells. Immunity *49*, 120-133 e129.
984 10.1016/j.immuni.2018.06.007.
985 52. Racine, R., McLaughlin, M., Jones, D.D., Wittmer, S.T., MacNamara, K.C., Woodland, D.L., and
986 Winslow, G.M. (2011). IgM production by bone marrow plasmablasts contributes to long-term
987 protection against intracellular bacterial infection. J Immunol *186*, 1011-1021.
988 10.4049/jimmunol.1002836.
989 53. Wilmore, J.R., Gaudette, B.T., Gomez Atria, D., Hashemi, T., Jones, D.D., Gardner, C.A., Cole, S.D.,
990 Misic, A.M., Beiting, D.P., and Allman, D. (2018). Commensal Microbes Induce Serum IgA
991 Responses that Protect against Polymicrobial Sepsis. Cell Host Microbe *23*, 302-311 e303.
992 10.1016/j.chom.2018.01.005.
993 54. Baumgarth, N. (2011). The double life of a B-1 cell: self-reactivity selects for protective effector
994 functions. Nat Rev Immunol *11*, 34-46. 10.1038/nri2901.
995 55. Higgins, B.W., Shuparski, A.G., Miller, K.B., Robinson, A.M., McHeyzer-Williams, L.J., and
996 McHeyzer-Williams, M.G. (2022). Isotype-specific plasma cells express divergent transcriptional
997 programs. Proc Natl Acad Sci U S A *119*, e2121260119. 10.1073/pnas.2121260119.
998 56. Radbruch, A., Muehlinghaus, G., Luger, E.O., Inamine, A., Smith, K.G., Dorner, T., and Hiepe, F.
999 (2006). Competence and competition: the challenge of becoming a long-lived plasma cell.
1000 Nature reviews. Immunology *6*, 741-750. 10.1038/nri1886.
1001 57. Biajoux, V., Natt, J., Freitas, C., Alouche, N., Sacquin, A., Hemon, P., Gaudin, F., Fazilleau, N.,
1002 Espeli, M., and Balabanian, K. (2016). Efficient Plasma Cell Differentiation and Trafficking
1003 Require Cxcr4 Desensitization. Cell reports *17*, 193-205. 10.1016/j.celrep.2016.08.068.
1004 58. Pioli, P.D., Casero, D., Montecino-Rodriguez, E., Morrison, S.L., and Dorshkind, K. (2019). Plasma
1005 Cells Are Obligate Effectors of Enhanced Myelopoiesis in Aging Bone Marrow. Immunity *51*, 351-
1006 366 e356. 10.1016/j.immuni.2019.06.006.
1007 59. Pangrazzi, L., Meryk, A., Naismith, E., Koziel, R., Lair, J., Krismer, M., Trieb, K., and Grubeck-
1008 Loebenstein, B. (2017). "Inflamm-aging" influences immune cell survival factors in human bone
1009 marrow. European journal of immunology *47*, 481-492. 10.1002/eji.201646570.
1010 60. Wagner, A., and Weinberger, B. (2020). Vaccines to Prevent Infectious Diseases in the Older
1011 Population: Immunological Challenges and Future Perspectives. Frontiers in immunology *11*, 717.
1012 10.3389/fimmu.2020.00717.
1013 61. Fedele, G., Trentini, F., Schiavoni, I., Abrignani, S., Antonelli, G., Baldo, V., Baldovin, T., Bandera,
1014 A., Bonura, F., Clerici, P., et al. (2022). Evaluation of humoral and cellular response to four

1015 vaccines against COVID-19 in different age groups: A longitudinal study. Frontiers in immunology
1016 *13*, 1021396. 10.3389/fimmu.2022.1021396.

1017


A
Gated on live singlets
Tomato+YFP-
Tomato+YFP+
TdTomato
YFP
CD138-APC
CD3-V450
93.9
0.2
98.2
0.1
3.1
2.8
1.6
0.1
B
Gated on live singlets
No TAM
TAM
CD138-APC
CD3-V450
TdTomato
YFP
0
65.2
C
BEC x R26LSLYFP
Tamoxifen
oral gavage
4mg/day
RNA-seq
FACS
FACS
TEM
RNA-seq
FACS
FACS
-2 -1 0
5
30
90
150 (Days)
Bulk PC
(Tomato+YFP-)
LLPC
(Tomato+YFP+)
D
Gated on B220-TdTomato+ PCs
D5
D30
D90
D150
Bone marrow
Spleen
Young
(6-8wks)
Middle-aged
(20-24wks)
65.0
14.3
9.3
1.8
65.2
36.8
25.5
16.0
62.9
11.5
4.5
0.9
61.7
16.7
8.6
3.2
TdTomato
YFP
E
Bone marrow
Middle-aged
Young
%YFP+ of PCs
ns
**
**
****
D5
D30
D90
D150
F
Spleen
Middle-aged
Young
%YFP+ of PCs
ns
ns
*
**
D5
D30
D90
D150
G
Bone marrow
Middle-aged
Young
# of YFP+PCs
D5
D30
D90
D150
t1/2 = 92.88d
t1/2 = 58.34d
Days
H
Spleen
Middle-aged
Young
# of YFP+PCs
D5
D30
D90
D150
t1/2 = 38.72d
t1/2 = 27.81d
Days


A
BEC x Blimp1YFP
x R26LSL-TdTomato
Tamoxifen
oral gavage
4mg/day
-2 -1 0
Two-photon
laser scanning microscopy
5
30
60
FACS validation
B
Gated on live non-T singlets
CD138-APC
YFP
TdTomato
Tomatobright
Tomatodim
Bulk PC
(TomatodimYFP+)
LLPC
(TomatobrightYFP+)
CXCR4
CD93
D5
D60
% of max
BV421
BUV615
C
LLPC
Bulk PC
0:00:00
1:00:31
2:01:03
2:22:14
2:55:31
3:56:03
7µm
D
Bulk PC
LLPC
Middle-aged
Young
D5
D30
D60
Y Distance (µm)
X Distance (µm)
Track velocity (µm/min)
Displacement velocity (µm/min)
Mean-squared displacement (µm²)
Time (min)
ns
***
****
**
*
m = 2.4 µm²min⁻¹
m = 2.2 µm²min⁻¹
m = 3.5 µm²min⁻¹
m = 1.2 µm²min⁻¹
m = 5.0 µm²min⁻¹
m = 1.5 µm²min⁻¹
m = 3.5 µm²min⁻¹
m = 1.2 µm²min⁻¹
m = 3.7 µm²min⁻¹
m = 1.6 µm²min⁻¹
E
% of cells over 1µm/min
Bulk PC
LLPC
D30
D60
F
50µm
LLPC
Bulk PC
Cluster Surface
G
% cells in cluster
P = 0.0517
% time in cluster per cell
D30
D60
H
Nearest neighbor analysis
Bulk PC
LLPC
I
Avg. Dist. to 20 nearest neighbor cells
Middle-aged
Young


A
Age
Tissue
Timepoint
CD93
CD81
CD37
CXCR4
CD326
CD44
CD48
CD126
CD147
CD138
CD53
CD49d
CD319
CD28
CD269
CD79b
CD98
CD268
CD267
Young
Middle-aged
Bone marrow
Spleen
D5
D30
D90
D150
B
CD93
CD81
CXCR4
CD326
CD44
CD48
Bulk PC
LLPC
% of max
BUV615
PerCPCy5.5
BV421
BB515
BV570
PECy5
C
Bone marrow
Spleen
%CD93+
Bulk PC
LLPC
D5
D30
D90
D150
D
CD48
CD93
CD44
CD81
CXCR4
CD326
Fold change
BM
SP
Average LLPC
IgG LLPC
IgM LLPC
IgA LLPC
E
%2-NBDG+
LLPC
Bulk PC
D5
D90
D150
Bone marrow
Spleen
F
Gated on live CD4-CD8-B220-TdTomato+ PCs
No enrichment
LLPC panel
TdTomato
YFP
3.4
20.4
G
Wildtype mouse
% of total PCs
Young
Middle-aged
0.1615
Bone marrow
Spleen


A
BEC-YFP
or
BEC-YFP-Cxcr4fl/fl
NP32-KLH/Alum
50μg/mouse, i.p.
Tamoxifen
oral gavage
4mg/day
ELISA
ELISA
-30
-3 -2 -1 0
30
60
FACS
(Days)
ELISA
B
anti-NP IgG
pre-TAM
anti-NP IgG (x10³μg/ml)
ns
% remaining pre-TAM Ab
WT
CXCR4cKO
D30
D60
C
2-ΔΔCt (relative to Actb)
WT
CXCR4cKO
D
Bone marrow
Spleen
NP+PC #
Bulk PC
LLPC
E
CD45.1/.2 Blimp1YFP BEC R26LSL-TdTomato(50%):
CD45.2 BEC R26LSL-YFP Cxcr4fl/fl(50%)
Mixed BM chimera
TAM
oral gavage
4mg/day
FACS
950RAD
CD45.1 host
-56
-3 -2 -1 0
5
30
90 (Days)
FACS
F
Bone marrow
Spleen
Labeled PC #
D5
D30
D90
G
Normalized labeled PC #
H
PC competency (CXCR4cKO:WT)
I
PC Mcl1 (gMFI x10³)
Untreated
1.1X
1.4X
1.5X
1.7X
1.0X
1.3X
1.4X
1.4X
J
PC Bcl2 (gMFI 10⁴)
1.1X
1.2X
1.4X
1.7X
1.3X
1.1X
1.9X
2.7X


A
CD45.1/.2 Blimp1YFP BEC R26LSL-TdTomato(50%):
CD45.2 BEC R26LSL-YFP Cxcr4fl/fl(50%)
Mixed BM chimera
950RAD
CD45.1 host
-56
4-OH-TAM
i.t. 5µg/tibia
FACS
-1
0
1
3
14 (Days)
PBS or
PTX i.v.
5µg/mouse
B
Day 1
labeled of PCs (x10³)
WT
CXCR4cKO
Injected Tibia
Contralateral bones
Ipsilateral femur
Spleen
C
labeled PCs (x10³)
Injected Tibia
Contralateral bones
Ipsilateral femur
Spleen
(Days)
WT
CXCR4cKO
D
Injected Tibia
Contralateral bones
Ipsilateral femur
Spleen
WT
CXCR4cKO
11.4
0.4
0.3
0.2
1.3
1.0
1.1
1.2
TdTomato
CD45.2-BV650
YFP
E
D1 CXCR4cKO post TAM
D1 WT post TAM
# of labeled PC (x10³)
PBS
PTX


A
Tissue
PC Type
Mouse Age
Groups
Tissue
Bone marrow
Spleen
PC Type
Bulk PC
LLPC
Mouse Age
Young
Middle-aged
B
Intersected DEGs
Total DEGs
SPLEEN D5 CONTROL
BM D5 CONTROL
BM OLD LLPC
BM YOUNG LLPC
SPLEEN OLD LLPC
SPLEEN YOUNG LLPC
C
DEG overlap
Unique
2 groups
3 groups
4 groups
580
182
104
32
SPLEEN YOUNG LLPC
SPLEEN OLD LLPC
BM YOUNG LLPC
BM OLD LLPC
D
GO TERMS
CONTROL
LLPC vs Bulk PC
MHCII
Cytokine and Signaling
Motility & Adhesion
Neural
Survival
Physiology
Proliferation
Leukocyte activation (GO:0045321)
MHC class II complex assembly (GO:0002399)
Lymphocyte activation (GO:0046649)
Regulation of IFNg production (GO:0032649)
Positive regulation of IFNg production (GO:0032729)
Ig production in immune response (GO:0002381)
Regulation of IL-10 production (GO:0032653)
Regulation of IL-6 production (GO:0032675)
Regulation of TNF production (GO:0032680)
Negative regulation of IL-12 production (GO:0032695)
Interleukin-1 beta production (GO:0032611)
MAPK cascade (GO:0000165)
Regulation of PI3-kinase signaling (GO:0014066)
Leukocyte cell-cell adhesion (GO:1903039)
Leukocyte migration (GO:0050900)
Cell chemotaxis (GO:0060326)
Nervous system process (GO:0050877)
Sensory perception (GO:0007600)
Response to acetylcholine (GO:1905144)
Regulation of angiogenesis (GO:0045765)
Response to stress (GO:0006950)
Apoptotic signaling pathway (GO:0097190)
Cell death (GO:0008219)
Regulation of sequestering of Ca2+ ion (GO:0051282)
Cellular lipid metabolic process (GO:0044255)
Glutathione metabolic process (GO:0006749)
Stress response to metal ion (GO:0097501)
Lactate transport (GO:0015727)
Mitotic cell cycle (GO:0000278)
Leukocyte proliferation (GO:0070661)
Regulation of chromosome separation (GO:1905818)
BM D5 CONTROL
SPLEEN D5 CONTROL
BM OLD LLPC
BM YOUNG LLPC
SPLEEN OLD LLPC
SPLEEN YOUNG LLPC
%UP
-log10(pvalue)
E
Surface proteins
SPLEEN
BONE MARROW
Bulk PC
LLPC
Groups
F
Transcription factors
SPLEEN
BONE MARROW
Bulk PC
LLPC
Groups


A
MA spleen LLPC
MA spleen bulk PC
young spleen LLPC
young spleen bulk PC
Day 5 spleen YFP+
Day 5 spleen YFP-
MA BM LLPC
MA BM bulk PC
young BM LLPC
young BM bulk PC
Day 5 BM YFP+
Day 5 BM YFP-
0.0
0.5
1.0
fraction of total
IgA
IgD
IgE
IgG1
IgG2b
IgG2c
IgG3
IgM
P<0.0001
P<0.001
P<0.01
P<0.05
B
IgH diversity
Chao1
800
600
400
200
0
**
Day 5
Middle-aged
Young
Total Bulk PC
Total LLPC
Day 90
C
Intra-mouse overlap
Shared clones(%)
0.20
0.15
0.10
0.05
0.00
*
*
**
*
Day 90 middle-aged
Day 90 young
Day 5 (control)
BM YFP+::BM YFP-
BM YFP+::spleen YFP-
BM YFP+::spleen YFP+
spleen YFP+::spleen YFP-
spleen YFP+::BM YFP-
BM YFP- ::spleen YFP-
D
Mutational Frequency
(per clones)
0.10
0.05
0.00
0.012
0.69
****
****
****
****
****
****
****
BM YFP-
BM YFP+
SPL YFP-
SPL YFP+
Day 5
Middle-aged
Day 90
Young
Day 90
E
SHM
Mutational Frequency
(per mouse)
0.05
0.04
0.03
0.02
0.01
0.00
*
*
*
**
***
**
BM YFP-
BM YFP+
SPL YFP-
SPL YFP+
Day 5
Middle-aged
Day 90
Young
Day 90
F
public clones
Frequency
0.020
0.015
0.010
0.005
0.000
****
****
****
All samples
day 5
Middle-aged
young
Day 90
G
Public Clones
LLPC enrichment
1.0
0.5
0.0
0.0
0.5
1.0
Total PC enrichment
H
Total Clones
LLPC
Other PC
Total=26144
Top Public Clones
Total=100
I
IGHV1-5: CTRPSLGPFAYW
IGHV7-3: CARYDYW
IGHV6-3: CTGPSDYW
IGHV1-81: CARRVTVVGTDYW
IGHV1-72: CAREGYYDEMDYW
IGHV7-3: CARYPDYW
IGHV7-1: CARDDGYYWYFDVW
IGHV7-1: CARDDYDWYFDVW
IGHV5-6: CARLNYFDYW
IGHV3-6: CASYSNFDYW
IGHV1-81: CARVTTVVAHFDYW
IGHV1-53: CARDAWFAYW
IGHV1-19: CARSPLDYW
IGHV2-2: CARNWDYW
IGHV2-9-1: CARNYYAMDYW
IGHV5-17: CARDDYDYAMDYW
IGHV7-1: CARDGNYWYFDVW
IGHV9-1: CVTAWFAYW
CLONESS
2
2
2
3
3
3
6
3
3
2
3
3
4
4
2
3
5
3
0
5
10
15
SAMPLES
MA Spleen LLPC
MA BM LLPC
Young Spleen LLPC
Young BM LLPC
Bulk PC samples